The present invention relates to a syringe device comprising a mechanism for preventing ejection of a dose exceeding a set dose. In particular the present invention relates to a syringe device comprising two independent mechanisms for preventing ejection of a dose exceeding a set dose.
When drugs are to be injected into the human body, it may have serious or even lethal consequences if the injected dose exceeds the set dose. Accordingly, it is important that the syringe devices comprises means for limiting ejection to the set dose.
It is an object of the present invention to provide a syringe device comprising means for prevention ejection of a dose exceeding the set dose. Furthermore, as such means may fail, it is an object of the present invention to provide a syringe device comprising a safety mechanism adapted to prevent ejection of a dose exceeding the set dose if the means for preventing fails.
The present invention relates to a syringe device for ejecting a dose of a medicament, the syringe device comprising:
An advantage of the present invention is that if a dose limiting mechanism fails to limit the ejected dose, the security mechanism is activated, and, thus, provides an extra safety for the patient.
In one embodiment the dose limiting mechanism and the safety mechanism are two independent mechanisms working independently from each other.
In one embodiment the two mechanisms are adapted to simultaneously prevent ejection of a dose exceeding the set dose. In another embodiment the safety mechanism is only activated if the dose limiting mechanism fails to prevent ejection of a dose exceeding the set dose. In one embodiment the two mechanisms are arranged such that even if the dose limiting mechanism fails, the safety mechanism is activated instantaneously such that the ejected dose does not exceed the set dose. In another embodiment the ejected dose is insignificantly larger than the set dose, if the dose limiting mechanism fails and the safety mechanism is activated. By insignificantly larger is meant that the change in dose is too small to have serious or fatal consequences.
The housing may define a passage for the piston rod, the passage may have a threaded inner surface for engagement with a threaded outer surface of the piston rod, the piston rod may be arranged with respect to the housing such that rotation of the piston rod relative to the housing causes the piston rod to be displaced translationally relative to the housing.
In one embodiment at least one of the dose limiting mechanism and the safety mechanism is adapted to limit relative rotational movement between the piston rod and the housing, to a rotation corresponding to ejection of the set dose. This may be the case, when the piston rod comprises a threaded outer surface adapted to engage a threaded inner surface of the housing. Accordingly, rotational locking of the piston rod (relative to the housing) results in a translational locking of the piston rod relative to the housing.
The dose limiting mechanism may comprise at least one first stopping surface adapted to engage at least one corresponding second stopping surface of the housing. Furthermore, rotation of the dose setting member during dose setting may cause the first stopping surface to move away from the second stopping surface and rotation during dose ejection may cause the first and the second surface(s) to move towards each other. Furthermore, ejection of a dose may be prevented when the first stopping surface abut the second stopping surface. The dose setting member may comprise the at least one first stopping surface. Alternatively, or as a supplement, the dose setting member may be coupled to a cylinder comprising a first stopping surface, and said cylinder may be adapted to indicate the set dose. The first and second stopping surfaces may be substantially plane surfaces which may extend in a direction parallel with the axial direction of the syringe device. Alternatively, the stopping surfaces may extend in a plane transverse to the axial direction, such as a plane orthogonal to the axial direction.
In one embodiment the safety mechanism comprises: a limiter defining a passage for the piston rod, the passage of the limiter defining a threaded inner surface for engagement with the threaded outer surface of the piston rod, and a driver defining a passage for the limiter, the driver being rotationally retained in relation to the limiter, the driver being coupled to the dose setting member such that rotation of the dose setting member during dose setting causes the driver to rotate, wherein relative rotation between the drive and the piston rod during dose setting causes the limiter to move away from a stopping position wherein the limiter prevents ejection of a dose.
In one embodiment the syringe device is adapted to prevent setting of a dose which exceeds the amount of a medicament in a reservoir of the syringe device. In such embodiments, the piston rod may comprise an end-of-dose stopping surface adapted engage a corresponding surface of the limiter, when the set dose corresponds to the amount of the medicament in the reservoir of the device. Accordingly, in such embodiments the limiter serves two functions, a first function being prevention of setting of a dose exceeding the amount of the medicament left in the reservoir and a second function being a security function adapted to prevent ejection of a dose exceeding the set dose.
Moreover, the syringe device may comprise an ejection assisting system for providing an ejection force for assisting an operator of the device in forcing the piston in said distal direction so as to eject the set dose. The ejection assisting system may be adapted to force the piston in the distal direction so as to eject the dose, without the aid of the user, when the user has initiated the ejection.
The ejection assisting system may comprise a spring, such as a torsional spring which is arranged to rotate the driver relative to the housing. The spring may be pre-strained when limiter is in the stopping position. Especially when the spring is pre-strained, the redundant security system of the present invention is advantageous, as accidental un-straining of the pre-strained spring, may cause the piston rod to rotate (and thus move translationally) corresponding to a lethal dose, such as 100 IU of insulin.
The invention will now be described in further detail with reference to
The syringe device comprises an ejection assisting system in the form of a pre-strained torsional spring 23 extending between the driver 10 and a proximal part 20 of the housing. Accordingly, when the dose setting member 8 is rotated to set a dose, the spring is strained even further.
The piston rod 6 comprises a threaded outer surface 22 adapted to engage a corresponding threaded inner surface of the housing 24 and accordingly rotation of the piston rod relative to the housing causes the piston rod to move translationally in relation to the housing. The threaded outer surface 22 of the piston rod also engages a threaded inner surface 26 of a limiter 28, which in
Moreover, an upper end-of-content surface 36 of the limiter 28 is adapted to engage a lower end-of-content surface 38 of a T-shaped end part 40 of the piston rod. The end-of-content surfaces are adapted to engage, when the set dose corresponds to the amount of a medicament remaining in a reservoir (not shown) of the device. Accordingly, the engagement of the end-of-content surfaces prevents setting of a dose exceeding the amount of a medicament remaining in the reservoir. It will be appreciated that the distance between the end-of-content surfaces thus corresponds to the amount of the medicament remaining in the reservoir.
Moreover, an upper surface 11 of the drum 12 may be adapted to engage a lower surface 13 of the housing, when the maximum dose is set. The maximum dose is the largest dose which may be set for each ejection (provided that the syringe device comprises the required amount of medicament). The maximum dose does not correspond to the end-of-content dose which relates the remaining amount of a medicament in the device. Accordingly, as long as the remaining amount of medicament in the device is larger than the maximum dose, the end-of-content surfaces will not abut each other during dose setting, whereas when the remaining amount of medicament in the device is lower than the maximum dose, the maximum dose surfaces will not abut each other during dose setting, as the end-of-content surfaces prevents further rotation.
The limiter 28 and the driver 10 are locked for relative rotation by means of grove-tongue engagement 42. Thus, when the piston rod is locked for rotation relative to the housing, a relative rotation between the driver 8 and the piston rod 6 causes the limiter to move away from the stopping position and towards the t-shaped end part 40 (i.e. upwards in the FIGURE). The piston rod is locked for rotation relative to the housing when the piston rod guide 34 is locked for rotation relative to the housing (not shown), as the piston rod guide 34 and the piston rod are locked for relative rotation due to the grove-tongue engagement 44.
The driver 12 and the piston rod guide 34 are interconnected by a two-way ratchet mechanism 46 comprising at least one first retaining member 48 defined by the driver 12 and at least one second retaining member 50 defined by the piston rod guide 34. The two-way ratchet mechanism is adapted to allow relative rotational movement between the driver 12 and the piston rod guide 34 during dose setting and to ensure that rotational movement of the driver during dose ejection is transferred to the piston rod guide 34.
The use of the device is as follows. Initially the piston rod guide is locked for rotation relative to the housing. Then the dose setting member is rotated, which causes the driver and the drum scale to rotate and the pre-strained spring to be strained even further. At the same time the limiter moves towards the T-shaped end part. If the user tries to set a dose exceeding the amount of medicament in the device, the limiter abuts the T-shaped end part whereby an even larger dose cannot be set. The dose is ejected by removing the rotational lock between the piston rod guide 34 and the housing whereby the strained spring forces the driver to rotate. The rotating driver forces the piston rod guide to rotate which again forces the piston rod to rotate. Due to the grove-tongue engagement 44 and the threaded interconnection between the piston rod and the housing, the rotating piston rod is forced to move forward and thus the medicament is expelled from the device.
Number | Date | Country | Kind |
---|---|---|---|
05016286 | Jul 2005 | EP | regional |
This application is a 35 U.S.C. § 371 national stage application of International Patent Application PCT/EP2006/007006 (published as WO 2007/017053), filed Jul. 17, 2006, which claimed priority of European Patent Application 05016286.6, filed Jul. 27, 2005; this application further claims priority under 35 U.S.C. § 119 of U.S. Provisional Application 60/708,211, filed Aug. 15, 2005.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/EP2006/007006 | 7/17/2006 | WO | 00 | 3/20/2008 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2007/017053 | 2/15/2007 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
4498904 | Turner et al. | Feb 1985 | A |
4865591 | Sams | Sep 1989 | A |
4883472 | Michel | Nov 1989 | A |
5104380 | Holman et al. | Apr 1992 | A |
5921966 | Bendek et al. | Jul 1999 | A |
5938642 | Burroughs et al. | Aug 1999 | A |
6221046 | Burroughs et al. | Apr 2001 | B1 |
6221053 | Walters et al. | Apr 2001 | B1 |
6235004 | Steenfeldt-Jensen et al. | May 2001 | B1 |
6248095 | Giambattista et al. | Jun 2001 | B1 |
6569123 | Alchas et al. | May 2003 | B2 |
6582404 | Klitgaard et al. | Jun 2003 | B1 |
6585698 | Packman et al. | Jul 2003 | B1 |
6663602 | Møller | Dec 2003 | B2 |
6699224 | Kirchhofer et al. | Mar 2004 | B2 |
6899699 | Enggaard | May 2005 | B2 |
7104972 | Moller et al. | Sep 2006 | B2 |
7169132 | Bendek et al. | Jan 2007 | B2 |
7195616 | Diller et al. | Mar 2007 | B2 |
7309327 | Kirchhofer et al. | Dec 2007 | B2 |
7500966 | Hommann | Mar 2009 | B2 |
7553299 | Veasey et al. | Jun 2009 | B2 |
7686786 | Moller et al. | Mar 2010 | B2 |
7811263 | Burren et al. | Oct 2010 | B2 |
7828779 | Kirchhofer et al. | Nov 2010 | B2 |
8096978 | Markussen | Jan 2012 | B2 |
8357120 | Moller | Jan 2013 | B2 |
8444606 | Radmer et al. | May 2013 | B2 |
8721601 | Burren et al. | May 2014 | B2 |
8920383 | Enggaard et al. | Dec 2014 | B2 |
9775953 | Enggaard et al. | Oct 2017 | B2 |
20020120235 | Enggaard | Aug 2002 | A1 |
20020165500 | Bechtold et al. | Nov 2002 | A1 |
20050033244 | Veasey | Feb 2005 | A1 |
20050261634 | Karlsson | Nov 2005 | A1 |
20060270985 | Hommann et al. | Nov 2006 | A1 |
20080208142 | Moller | Aug 2008 | A1 |
20080221530 | Glejbol et al. | Sep 2008 | A1 |
20150080812 | Enggaard et al. | Mar 2015 | A1 |
Number | Date | Country |
---|---|---|
20209051 | Apr 2003 | DE |
69810860 | Nov 2003 | DE |
69810860 | Nov 2003 | DE |
10229122 | Feb 2004 | DE |
10351596 | Jun 2005 | DE |
0897728 | Feb 1999 | EP |
897729 | Feb 1999 | EP |
0937471 | Aug 1999 | EP |
937476 | Aug 1999 | EP |
5016291.6 | Jul 2005 | EP |
1909870 | Apr 2008 | EP |
2002-503116 | Jan 2002 | JP |
2005-508205 | Mar 2005 | JP |
2091087 | Sep 1997 | RU |
2212254 | Sep 2003 | RU |
1528330 | Dec 1989 | SU |
WO 8702895 | May 1987 | WO |
1996027400 | Sep 1996 | WO |
2006114395 | Aug 1999 | WO |
9938554 | Aug 1999 | WO |
WO 0119434 | Mar 2001 | WO |
0195959 | Dec 2001 | WO |
02053214 | Jul 2002 | WO |
2002092153 | Nov 2002 | WO |
03011374 | Feb 2003 | WO |
WO 2004007003 | Jan 2004 | WO |
2004028598 | Apr 2004 | WO |
2004030730 | Apr 2004 | WO |
04078240 | Sep 2004 | WO |
2005018721 | Mar 2005 | WO |
2006045526 | May 2006 | WO |
06058883 | Jun 2006 | WO |
2006076921 | Jul 2006 | WO |
06089768 | Aug 2006 | WO |
06125328 | Nov 2006 | WO |
06125329 | Nov 2006 | WO |
Entry |
---|
Non-Final Office Action issued by the USPTO for U.S. Appl. No. 11/996,409 dated Dec. 31, 2008. |
Non-Final Office Action issued by the USPTO for U.S. Appl. No. 11/996,409 dated Aug. 25, 2009. |
Statement by Dr. Nils Basso printed May 8, 2010. |
Description of the Mechanical Components of the OPTICLIK Pen printed May 8, 2010. |
Anlage E23 Eidesstattliche Versichemng Herr Peter Ryser. |
Anlage E24 Eidesstattliche Versicherung Herr Nicolas Binggeli. |
Anlage E25 Eidesstattliche Versichemng Frau Daniela Moser. |
Offenkundige Vorbenutzung Durch Die Injektionsvorrichtung “Flexpen” E20a-c. |
Anlage E26 (Fig. 10). |
Notice of Opposition in EP1909870 dated Dec. 12, 2011. |
English Abstract of DE202009051 Published Apr. 24, 2003. |
Ypsomed AG Press Release Jan. 16, 2005 (German and English versions). |
Description of the Mechanical Components of the Opticlik Pen. |
Statement by Dr. Nils Basso. |
Google Translation of Affidavit by Dr. Nils Basso. |
Final Rejection in U.S. Appl. No. 11/996,409, filed Jan. 22, 2008 by Enggaard et al., dated Apr. 20, 2010. |
Number | Date | Country | |
---|---|---|---|
20080234634 A1 | Sep 2008 | US |
Number | Date | Country | |
---|---|---|---|
60708211 | Aug 2005 | US |